Agrochemicals company Astec Lifesciences announced Q2FY26 results The Company reported consolidated total income of Rs 74.8 crore in Q2FY26 as compared to Rs 100.5 crore in Q2FY25. The Company reported consolidated EBITDA loss of Rs 5.6 crore in Q2FY26 as compared to EBITDA loss of Rs 17.7 crore in Q2FY25. N B Godrej, Chairman, Astec LifeSciences, said: Astec recorded year-on-year and sequential improvement in its performance in Q2FY26. The EBITDA loss narrowed to Rs 5.6 crore, reflecting a positive trend compared to previous quarters. This improvement was largely driven by higher volumes and better gross margins in the Enterprise business. Conversely, the contract manufacturing segment experienced a YoY revenue decline, as the cautious stance adopted by the contract manufacturing customers impacted performance during the quarter. Result PDF